R. Stupp and F. Roila, Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Annals of Oncology, vol.20, pp.126-128, 2009.

M. Weller, T. Cloughesy, J. R. Perry, and W. Wick, Standards of care for treatment of recurrent glioblastoma-are we there yet?, Neuro-Oncology, vol.15, issue.1, pp.4-27, 2013.

S. H. Chen, H. D. Shine, J. C. Goodman, R. G. Grossman, and S. L. Woo, Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo, Proceedings of the National Academy of Sciences of the United States of America, vol.91, issue.8, pp.3054-3057, 1994.

P. J. Choi, R. S. Tubbs, and R. J. Oskouian, Emerging Cellular Therapies for Glioblastoma Multiforme, Cureus, vol.10, issue.3, p.2305, 2018.

L. Zhu, Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells, Frontiers in Immunology, vol.9, p.824, 2018.

D. S. Chung, H. J. Shin, and Y. K. Hong, A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy, Journal of Immunology Research, p.326545, 2014.

E. Vauleon, T. Avril, B. Collet, J. Mosser, and V. Quillien, Overview of cellular immunotherapy for patients with glioblastoma, Clinical and Developmental Immunology, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00532866

C. E. Brown, Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy, The New England Journal of Medicine, vol.375, issue.26, pp.2561-2569, 2016.

U. Jarry, Stereotaxic administrations of allogeneic human Vgamma9Vdelta2 T cells efficiently control the development of human glioblastoma brain tumors, Oncoimmunology, vol.5, issue.6, p.1168554, 2016.

V. Dutoit, Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy, Brain, vol.135, pp.1042-1054, 2012.

N. Joalland, IL-21 Increases the Reactivity of Allogeneic Human Vgamma9Vdelta2 T Cells Against Primary Glioblastoma Tumors, Journal of Immunotherapy, vol.41, issue.5, pp.224-231, 2018.

B. Clemenceau, Effector memory alphabeta T lymphocytes can express FcgammaRIIIa and mediate antibody-dependent cellular cytotoxicity, The Journal of Immunology, vol.180, issue.8, pp.5327-5334, 2008.

M. G. Abdelwahab, T. Sankar, M. C. Preul, and A. C. Scheck, Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas, Journal of Visualized Experiments, issue.57, p.3403, 2011.

U. Jarry, Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection, Journal of Neuroimmunology, vol.267, issue.1-2, pp.35-42, 2014.

C. H. June, R. S. O'connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, CAR T cell immunotherapy for human cancer. Science, vol.359, issue.6382, pp.1361-1365, 2018.

E. N. Baruch, A. L. Berg, M. J. Besser, J. Schachter, and G. Markel, Adoptive T cell therapy: An overview of obstacles and opportunities, Cancer, vol.123, issue.S11, pp.2154-2162, 2017.

N. L. Bryant, Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma, Neuro-Oncology, vol.11, issue.4, pp.357-367, 2009.

L. Pereboeva, L. Harkins, S. Wong, and L. S. Lamb, The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation, Cancer Immunology, Immunotherapy, vol.64, issue.5, pp.551-562, 2015.

S. L. Bailey, P. A. Carpentier, E. J. Mcmahon, W. S. Begolka, and S. D. Miller, Innate and adaptive immune responses of the central nervous system, Critical Reviews in Immunology, vol.26, issue.2, pp.149-188, 2006.

A. Louveau, Structural and functional features of central nervous system lymphatic vessels, Nature, vol.523, issue.7560, pp.337-341, 2015.

P. Menei, Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study, Cancer, vol.86, issue.2, pp.325-330, 1999.

P. Menei, Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma, Cancer, vol.100, issue.2, pp.405-410, 2004.

S. Salot, Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product, Journal of Immunological Methods, vol.326, issue.1-2, pp.63-75, 2007.

J. Bennouna, Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma, Cancer Immunology, Immunotherapy, vol.57, issue.11, pp.1599-1609, 2008.

S. K. Singh, Identification of human brain tumour initiating cells, Nature, vol.432, issue.7015, pp.396-401, 2004.